The Subjective Effects of Psychedelics May Not Be Necessary for Their Enduring Therapeutic Effects
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Psychedelics represent one of the most promising classes of experimental medicines for the treatment of neuropsychiatric disorders due to their ability to promote neural plasticity and produce both rapid and sustained therapeutic effects following a single administration. Conventional wisdom holds that peak mystical experiences induced by psychedelics are a critical component of their therapeutic mechanisms of action, though evidence supporting that claim is largely correlational. Here, I present data suggesting that the subjective effects induced by psychedelics may not be necessary to produce long-lasting changes in mood and behavior. Understanding the role of subjective effects in the therapeutic mechanisms of psychedelics will have important implications for both basic neuroscience and for increasing patient access to the next generation of medicines developed as a result of psychedelic research.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Whiteford, H. A., Degenhardt, L., Rehm, J., Baxter, A. J., Ferrari, A. J., Erskine, H. E., Charlson, F. J., Norman, R. E., Flaxman, A. D., Johns, N., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61611-6 · Cited by 6,006
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
NMDAR inhibition-independent antidepressant actions of ketamine metabolites
Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., Alkondon, M., Yuan, P., Pribut, H. J., Singh, N. S., et al. (2016) · Nature · doi:10.1038/nature17998 · Cited by 1,609
New approaches to antidepressant drug discovery: beyond monoamines
Berton, O., & Nestler, E. J. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1846 · Cited by 1,589
Psychedelics promote structural and functional neural plasticity
Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.022 · Cited by 1,207
Self-citationPsilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P., & Strassman, R. J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565144 · Cited by 1,151
Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A., Vogel, H., & Hell, D. (1998) · NeuroReport · doi:10.1097/00001756-199812010-00024 · Cited by 1,018
Roseman, L., Nutt, D. J., & Carhart-Harris, R. L. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00974 · Cited by 808
Cited by
Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo
Shao, L.-X., Liao, C., Gregg, I., Davoudian, P. A., Savalia, N. K., Delagarza, K., & Kwan, A. C. (2021) · Neuron · doi:10.1016/j.neuron.2021.06.008 · Cited by 626
The subjective effects of psychedelics are necessary for their enduring therapeutic effects
Yaden, D. B., & Griffiths, R. R. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00194 · Cited by 541
von Rotz, R., Schindowski, E. M., Jungwirth, J., Schuldt, A., Rieser, N. M., Zahoranszky, K., Seifritz, E., Nowak, A., Nowak, P., Jäncke, L., et al. (2023) · eClinicalMedicine · doi:10.1016/j.eclinm.2022.101809 · Cited by 354
Psychedelics, mystical experience, and therapeutic efficacy: a systematic review
Ko, K., Knight, G., Rucker, J. J., & Cleare, A. J. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.917199 · Cited by 306
“Olson (39) has suggested that subjective experience may not be necessary for the therapeutic outcome, arguing that an increase in neural plasticity has its own value and would occur independent of the phenomenon; thus, non-hallucinogenic properties of psychedelics may be isolated for use.”
BackgroundThe neural basis of psychedelic action
Kwan, A. C., Olson, D. E., Preller, K. H., & Roth, B. L. (2022) · Nature Neuroscience · doi:10.1038/s41593-022-01177-4 · Cited by 302
Self-citationTherapeutic alliance and rapport modulate responses to psilocybin assisted therapy for depression
Murphy, R., Kettner, H., Zeifman, R., Giribaldi, B., Kartner, L., Martell, J., Read, T., Murphy-Beiner, A., Baker-Jones, M., Nutt, D., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.788155 · Cited by 250
“This finding enriches recent debates about the necessity of the subjective psychedelic experience for enduring therapeutic effects (Olson, 2021; Yaden and Griffiths, 2021) and the increasing interest in developing non-hallucinogenic analogues of psychedelic compounds (Cameron et al.”
BackgroundInfluentialAday, J. S., Heifets, B. D., Pratscher, S. D., Bradley, E., Rosen, R., & Woolley, J. D. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06123-7 · Cited by 237
“Although intuitive, this hypothesis is nonetheless unproven and a thorough evaluation is beyond the scope of this review; we instead refer the reader to an excellent summary of arguments for and against this idea (Olson 2020; Yaden and Griffiths 2020).”
Aday, J. S., Davis, A. K., Mitzkovitz, C. M., Bloesch, E. K., & Davoli, C. C. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00014 · Cited by 224
de la Fuente Revenga, M., Zhu, B., Guevara, C. A., Naler, L. B., Saunders, J. M., Zhou, Z., Toneatti, R., Sierra, S., Wolstenholme, J. T., Beardsley, P. M., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109836 · Cited by 224
“One of the still-open questions in the field is whether the subjective effects of psychedelics are necessary or complementary for their post-acute clinically relevant outcomes in patients with severe psychiatric disorders such as depression (Olson, 2020; Yaden and Griffiths, 2020).”
Psychedelic-inspired drug discovery using an engineered biosensor
Dong, C., Ly, C., Dunlap, L. E., Vargas, M. V., Sun, J., Hwang, I.-W., Azinfar, A., Oh, W. C., Wetsel, W. C., Olson, D. E., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.043 · Cited by 213
Self-citationPsychedelics and Other Psychoplastogens for Treating Mental Illness.
Vargas, M. V., Meyer, R., Avanes, A. A., Rus, M., & Olson, D. E. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.727117 · Cited by 166
Self-citationMicrodosing with psilocybin mushrooms: a double-blind placebo-controlled study
Cavanna, F., Muller, S., de la Fuente, L. A., Zamberlan, F., Palmucci, M., Janeckova, L., Kuchar, M., Pallavicini, C., & Tagliazucchi, E. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-02039-0 · Cited by 134
“The use of low doses of psychedelics constitutes an attractive therapeutic model, since it could circumvent the potential issues associated with altered consciousness and challenging experiences elicited by higher doses [24].”
BackgroundA non-hallucinogenic LSD analog with therapeutic potential for mood disorders
Lewis, V., Bonniwell, E. M., Lanham, J. K., Ghaffari, A., Sheshbaradaran, H., Cao, A. B., Calkins, M. M., Bautista-Carro, M. A., Arsenault, E., Telfer, A., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112203 · Cited by 164
“30,86 Intravenous infusion of 18– 22 mg 2-Br-LSD produced more intense effects, such as deper-sonalization, derealization, and mild confusion.”
BackgroundAdverse Events in Studies of Classic Psychedelics: A Systematic Review and Meta-Analysis
Hinkle, J. T., Graziosi, M., Nayak, S. M., & Yaden, D. B. (2024) · JAMA psychiatry · doi:10.1001/jamapsychiatry.2024.2546 · Cited by 156
Biochemical Mechanisms Underlying Psychedelic-Induced Neuroplasticity
Olson, D. E. (2022) · Biochemistry · doi:10.1021/acs.biochem.1c00812 · Cited by 129
Self-citationTimmermann, C., Bauer, P. R., Gosseries, O., Vanhaudenhuyse, A., Vollenweider, F., Laureys, S., Singer, T., Antonova, E., & Lutz, A. (2023) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2022.11.006 · Cited by 150
5-HT2ARs Mediate Therapeutic Behavioral Effects of Psychedelic Tryptamines
Cameron, L. P., Patel, S. D., Vargas, M. V., Barragan, E. V., Saeger, H. N., Warren, H. T., Chow, W. L., Gray, J. A., & Olson, D. E. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00718 · Cited by 118
“16 While the role of psychedelic-induced subjective effects in therapeutic outcomes is still highly debated, 17,18 the importance of structural plasticity has been appreciated as a hallmark of antidepressant efficacy for many years.”
Self-citationReckweg, J. T., Uthaug, M. V., Szabó, A., Davis, A. K., Lancelotta, R., Mason, N. L., & Ramaekers, J. G. (2022) · Journal of Neurochemistry · doi:10.1111/jnc.15587 · Cited by 134
“It has been postulated that such neurobiological, or “psychoplastogenic”, effects can be decoupled from the subjective effects of psychedelics through chemical design without losing therapeutic potential (Olson, 2021).”
BackgroundInfluentialMcCulloch, D. E.-W., Grzywacz, M. Z., Madsen, M. K., Jensen, P. S., Ozenne, B., Armand, S., Knudsen, G. M., Fisher, P. M., & Stenbæk, D. S. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.841648 · Cited by 125
“Our results indicate that the subjective nature of the psychedelic experience is indeed linked to lasting positive outcomes, though it is argued that such links may be mere epiphenomena (Hibicke et al., 2020; Olson, 2021).”
ResultErkizia-Santamaría, I., Alles-Pascual, R., Horrillo, I., Meana, J. J., & Ortega, J. E. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113612 · Cited by 119
Expectancy in placebo-controlled trials of psychedelics: if so, so what?
Butler, M., Jelen, L., & Rucker, J. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06221-6 · Cited by 100
“There have also been suggestions that administering psychedelics under general anaesthesia would be an effective means of probing their context-independent antidepressant effects (D. E. Olson 2020).”
BackgroundNeural Mechanisms and Psychology of Psychedelic Ego Dissolution
Stoliker, D., Egan, G. F., Friston, K. J., & Razi, A. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000508 · Cited by 81
Palitsky, R., Kaplan, D. M., Peacock, C., Zarrabi, A. J., Maples‐Keller, J. L., Grant, G. H., Dunlop, B. W., & Raison, C. L. (2023) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2023.1554 · Cited by 104
Does Psychedelic Therapy Have a Transdiagnostic Action and Prophylactic Potential?
Kočárová, R., Horáček, J., & Carhart-Harris, R. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.661233 · Cited by 96
Brennan, W., & Belser, A. B. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.866018 · Cited by 90
“…the putatively therapeutic neuropharmacology of classic psychedelics while eliminating their subjective effects (Dong et al., 2021)—and thereby the need for supportive therapy (Yakowicz, 2021)—the potential efficacy of this approach remains speculative (Yaden and Griffiths, 2020; Olson, 2021).”
BackgroundBender, D., & Hellerstein, D. J. (2022) · Psychopharmacology · doi:10.1007/s00213-021-06049-6 · Cited by 88
“A commonly referenced overarching mechanistic neurobiological principle is that psychedelic compounds act as psychoplastogens (Olson 2021), as potentiators of temporary neuroplasticity which can cause lasting alterations to neural pathways even after limited exposure.”
BackgroundSekssaoui, M., Bockaert, J., Marin, P., & Bécamel, C. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-024-01794-6 · Cited by 89
Tulver, K., Kaup, K., Laukkonen, R., & Aru, J. (2023) · Consciousness and Cognition · doi:10.1016/j.concog.2023.103494 · Cited by 95
Psychedelic perceptions: mental health service user attitudes to psilocybin therapy
Corrigan, K., Haran, M., McCandliss, C., McManus, R., Cleary, S., Trant, R., Kelly, Y., Ledden, K., Rush, G., O’Keane, V., et al. (2022) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-021-02668-2 · Cited by 84
An analog of psychedelics restores functional neural circuits disrupted by unpredictable stress
Lu, J., Tjia, M., Mullen, B., Cao, B., Lukasiewicz, K., Shah-Morales, S., Weiser, S., Cameron, L. P., Olson, D. E., Chen, L., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01159-1 · Cited by 84
“Although classical psychedelics appear efficacious in treating stress-induced psychiatric disorders, their hallucinogenic potential remains a significant drawback [35].”
BackgroundSelf-citationPsychedelics and Neural Plasticity: Therapeutic Implications
Grieco, S. F., Castrén, E., Knudsen, G. M., Kwan, A. C., Olson, D. E., Zuo, Y., Holmes, T. C., & Xu, X. (2022) · The Journal of Neuroscience · doi:10.1523/jneurosci.1121-22.2022 · Cited by 82
“The clinical use of psychedelics thus requires extensive patient preparation, monitoring, and follow-up, which is time-consuming and expensive ( Olson, 2020).”
Self-citationCritical Period Plasticity as a Framework for Psychedelic-Assisted Psychotherapy
Lepow, L., Morishita, H., & Yehuda, R. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.710004 · Cited by 85
“There remains debate about the centrality of the psychotherapy and the acute subjective experience in the psychedelic treatment (Heifets and Malenka, 2019; Olson, 2021; Yaden and Griffiths, 2021).”
BackgroundJohnston, J. N., Kadriu, B., Allen, J., Gilbert, J. R., Henter, I. D., & Zarate, C. A. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109422 · Cited by 75
Psychedelic‐inspired approaches for treating neurodegenerative disorders
Saeger, H. N., & Olson, D. E. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15544 · Cited by 74
“…effects of drugs like ketamine and serotonergic psychedelics might not be necessary for their sustained beneficial effects on neuroplasticity and behavior (Cameron & Olson, 2022; Olson, 2020; Peters & Olson, 2021), though this remains a subject of intense debate (Yaden & Griffiths, 2020).”
BackgroundSelf-citationWeiss, F., Magnesa, A., Gambini, M., Gurrieri, R., Annuzzi, E., Elefante, C., Perugi, G., & Marazziti, D. (2025) · Brain Sciences · doi:10.3390/brainsci15020117 · Cited by 74
“Others (“non-phenomenists”) deem that a psy-choplastogenic drug with the same neurobiological effects of psychedelics, but devoid of psychodysleptic properties, might equally attain the same clinical benefit [132].”
Toward Synergies of Ketamine and Psychotherapy
Mathai, D. S., Mora, V., & Garcia‐Romeu, A. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.868103 · Cited by 74
Therapeutic mechanisms of psychedelics and entactogens
Heifets, B. D., & Olson, D. E. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01666-5 · Cited by 79
“Cognitive flexibility 9,61,62 Experience-independent, circuit specific plasticity 44,46,49,50,52 Salient but nonspecific altered state 190,223,224 Disease-specificity • Stress models 44,48,105,107,127,199,200,214 • SUD 46,206–211 • ASD 141,212 Expectancy/priming 190,191,223 Fear extinction 59, 70–72…”
BackgroundSelf-citationPsychedelic therapy's transdiagnostic effects: A research domain criteria (RDoC) perspective
Kelly, J. R., Gillan, C. M., Prenderville, J., Kelly, C., Harkin, A., Clarke, G., & O'Keane, V. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.800072 · Cited by 69
“While, it is generally accepted that the quality of the subjective experience, dependent on the optimization of set and setting (context) is a critical component of the therapeutic mechanism of action of psychedelic therapy (87, 174), some propose that the subjective effects may not be necessary to produce long-lastin…”
BackgroundThe Emerging Field of Psychedelic Psychotherapy
Barber, G., & Aaronson, S. T. (2022) · Current Psychiatry Reports · doi:10.1007/s11920-022-01363-y · Cited by 68
Clinically relevant acute subjective effects of psychedelics beyond mystical experience
Yaden, D. B., Goldy, S. P., Weiss, B., & Griffiths, R. R. (2024) · Nature Reviews Psychology · doi:10.1038/s44159-024-00345-6 · Cited by 71
“Some research suggested that the acute subjective effects of psychedelics are not necessary to produce therapeutic benefits 32 .”
Aqil, M., & Roseman, L. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109300 · Cited by 69
“ported by studies in animal models, some authors have proposed neurobiological mechanisms, such as increased neuroplasticity (Ly et al., 2018; Olson, 2020; Lu et al., 2021; Lepow et al., 2021); others, supported by clinical studies in humans, have proposed “mystical-type””
BackgroundLeger, R. F., & Unterwald, E. M. (2021) · Journal of Psychopharmacology · doi:10.1177/02698811211044688 · Cited by 63
“those capable of producing alterations in perception) were included in this analysis, as it has been suggested that this is required to precipitate the drugs’ therapeutic effects (Yaden and Griffiths, 2021), though notably there has been some controversy regarding this necessity (Olson, 2021).”
BackgroundOn the need for metaphysics in psychedelic therapy and research
Sjöstedt-Hughes, P. (2023) · Frontiers in Psychology · doi:10.3389/fpsyg.2023.1128589 · Cited by 66
“Another point of metaphysical significance is that if it is the phenomenology rather than the physiology that is primarily therapeutically effective here (contra Olson, 2020), therewith comes an implicit assertion of mental causation.”
BackgroundRoméo, B., Kervadec, E., Fauvel, B., Strika-Bruneau, L., Amirouche, A., Bezo, A., Piolino, P., & Benyamina, A. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106086 · Cited by 68
Barker, S. A. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06065-0 · Cited by 58
“It has been suggested that a given compound’s ability to produce hallucinations may prove unnecessary (Olson, 2021) to produce enduring therapeutic effects.”
BackgroundLow doses of lysergic acid diethylamide (LSD) increase reward-related brain activity
Glazer, J. E., Murray, C. H., Nusslock, R., Lee, R., & de Wit, H. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-022-01479-y · Cited by 61
Hashimoto, K. (2024) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-024-01770-7 · Cited by 61
“It is also currently unclear whether mystical experiences induced by psych-edelics are associated with their antidepressant actions in patients with MDD [40–42].”
Mechanisms and molecular targets surrounding the potential therapeutic effects of psychedelics
Jaster, A. M., & González‐Maeso, J. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02274-x · Cited by 61
Psilocybin Facilitates Fear Extinction: Importance of Dose, Context, and Serotonin Receptors
Woodburn, S. C., Levitt, C. M., Koester, A., & Kwan, A. C. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00279 · Cited by 58
Kałużna, A., Schlosser, M., Craste, E. G., Stroud, J., & Cooke, J. E. (2022) · Journal of Psychedelic Studies · doi:10.1556/2054.2022.00199 · Cited by 62
“In terms of the current psychedelic debate, the present piece of research is relevant to the question of the therapeutic importance of psychedelic-induced subjective effects (Olson, 2021; Yaden & Grif fi ths, 2021).”
Aday, J. S., Skiles, Z., Eaton, N., Fredenburg, L., Pleet, M. M., Mantia, J., Bradley, E., Fernandes‐Osterhold, G., & Woolley, J. D. (2023) · Psychedelic Medicine · doi:10.1089/psymed.2022.0004 · Cited by 56
“25 However, some argue the subjective experience may not be necessary for the drugs’ therapeutic effects (see: Olson 26 ), and no research efforts to date have investigated whether personal psychedelic experience actually enhances competency for psychedelic therapists.”
Agin-Liebes, G., Ekman, E., Anderson, B., Malloy, M., Haas, A., & Woolley, J. (2024) · Journal of Humanistic Psychology · doi:10.1177/00221678211022949 · Cited by 51
“While some researchers have challenged the notion that the subjective, psychological effects are key drivers of clinical improvements (Olson, 2021), an accumulating number of studies indicate their importance (Yaden & Griffiths, 2021).”
BackgroundBrennan, B., Kelman, A. R., & Belser, A. (2023) · Psychedelic Medicine · doi:10.1089/psymed.2023.0007 · Cited by 52
“The reporting deficiencies also occur in the context of strong incentives to reduce the expected cost of PAT treatment in preparation for commercialization 91 by down-playing the role of PIs in favor of focusing on the pharmacological intervention alone.”
Stoliker, D., Novelli, L., Vollenweider, F. X., Egan, G. F., Preller, K. H., & Razi, A. (2024) · Biological Psychiatry · doi:10.1016/j.biopsych.2024.01.002 · Cited by 53
Magaraggia, I., Kuiperes, Z., & Schreiber, R. (2021) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2021.107467 · Cited by 49
“Based on the lack of head twitch responses observed in mice after administration, the latter being a validated measure for the hallucinogenic property of drugs, Olson and colleagues claimed to have developed such compounds (Cameron et al., 2021; Olson, 2020).”
BackgroundYu, Z., Burback, L., Winkler, O., Xu, L., Dennett, L., Vermetten, E. H. G. J. M., Greenshaw, A. J., Li, X., Milne, M., Wang, F., et al. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1386321 · Cited by 53
“…Olson also supports that these subjective experiences might be important in maximizing therapeutic outcomes (39), especially considering that mystical experiences consistently correlate with therapeutic ef fi cacy, potentially implicating psychological mechanisms or a potent placebo response (41).”
BackgroundA framework for assessment of adverse events occurring in psychedelic-assisted therapies
Palitsky, R., Kaplan, D. M., Perna, J., Bosshardt, Z., Maples‐Keller, J. L., Levin-Aspenson, H. F., Zarrabi, A. J., Peacock, C., Mletzko, T., Rothbaum, B. O., et al. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241265756 · Cited by 49
“Although it is possible that the psychedelic experience itself is epiphenomenal to the treatment effects of the intervention (Olson, 2021), given the perceived significance of the phenomenology of the psychedelic experience for patients, characteristics of this experience—and its post-dosing…”
Qu, Y., Chang, L., Ma, L., Wan, X., & Hashimoto, K. (2022) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2022.173500 · Cited by 48
A Brief Historical Overview of Psychedelic Research
Geyer, M. A. (2023) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2023.11.003 · Cited by 53
Psychedelics for acquired brain injury: a review of molecular mechanisms and therapeutic potential
Allen, J., Dames, S., Foldi, C. J., & Shultz, S. R. (2024) · Molecular Psychiatry · doi:10.1038/s41380-023-02360-0 · Cited by 47
Psilocybin history, action and reaction: A narrative clinical review
Sharma, P., Nguyen, Q. A., Matthews, S. J., Carpenter, E., Matthews, D. B., Patten, C. A., & Hammond, C. J. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231190858 · Cited by 44
“Furthur, it is to be noted that the clinical design of doubleblind placebo studies as described in the subsequent section for psilocybin-associated therapy is problematic because of incorporating “active placebos” into their designs, such as niacin or low doses (LDs) of psychedelics, as participants and researchers ma…”
BackgroundWeiss, B., Roseman, L., Giribaldi, B., Nutt, D. J., Carhart-Harris, R. L., & Erritzøe, D. (2024) · International Journal of Mental Health and Addiction · doi:10.1007/s11469-024-01253-9 · Cited by 49
“…scientists have raised the possibility that 5-HT 2A receptor occupancy and signaling (Madsen et al., 2019) and subsequent neurobiological processes are sufficient for psilocybin’s antidepressant effects, while subjective psychological effects are ancillary or perhaps even unnecessary (Olson, 2020).”
Peterson, A. H., Largent, E. A., Lynch, H. F., Karlawish, J. H., & Sisti, D. A. (2022) · AJOB Neuroscience · doi:10.1080/21507740.2022.2148771 · Cited by 43
“ive hallucinogenic experience, might confer an equivalent therapeutic benefit (Olson 2021).”
BackgroundEngineering Safer Psychedelics for Treating Addiction
Peters, J., & Olson, D. E. (2021) · Neuroscience Insights · doi:10.1177/26331055211033847 · Cited by 45
Self-citationOrłowski, P., Ruban, A., Szczypiński, J., Hobot, J., Bielecki, M., & Bola, M. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221089034 · Cited by 41
“Indirect effect of subjective aspects of psychedelic experiences To what extent acute subjective effects are necessary to observe lasting psychological changes induced by psychedelics is one of the key research questions in the psychedelics research field (Olson, 2021; Yaden and Griffiths, 2021).”
BackgroundThe Effects of Psychedelics on Neuronal Physiology
Hatzipantelis, C. J., & Olson, D. E. (2023) · Annual Review of Physiology · doi:10.1146/annurev-physiol-042022-020923 · Cited by 44
“Currently, it is unclear whether psychological or neurobiological effects mediate the therapeutic properties of psychedelics (for an overview of the current debate with examples, see 10, 11).”
Self-citationDistinctive But Not Exceptional: The Risks of Psychedelic Ethical Exceptionalism
Cheung, K., Earp, B. D., Patch, K., & Yaden, D. B. (2025) · The American Journal of Bioethics · doi:10.1080/15265161.2024.2433421 · Cited by 42
The Potential Role of Psychedelic Drugs in Mental Health Care of the Future
Gründer, G., & Jungaberle, H. (2021) · Pharmacopsychiatry · doi:10.1055/a-1486-7386 · Cited by 44
“The sustainability of psychedelic effects may be influenced by pharmacological and non-pharmacological factors such as the quality of the psychedelic experience and sociocultural factors that help to sustain beneficial attitudes and health behaviors in the individual [24, 25].”
BackgroundGarel, N., Drury, J., Lévesque, J. T., Goyette, N., Lehmann, A., Looper, K. J., Erritzøe, D., Dames, S., Turecki, G., Rej, S., et al. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1268832 · Cited by 40
“While even those claims have been challenged by methodological criticisms and emerging data (106, 107), psychedelic-assisted psychotherapy models for psilocybin are undeniably more formalized and better supported by clinical research than equivalent models for ketamine.”
BackgroundAarrestad, I. K., Cameron, L. P., Fenton, E. M., Casey, A. B., Rijsketic, D. R., Patel, S. D., Sambyal, R., Johnson, S. B., Ly, C., Viswanathan, J., et al. (2025) · Nature Neuroscience · doi:10.1038/s41593-025-02021-1 · Cited by 43
“While the role of psychedelic-induced subjective effects in therapeutic outcomes is still highly debated 20,21 , the importance of structural plasticity has been appreciated as a hallmark of antidepressant efficacy for many years 1,4,22,23 .”
Self-citationPsychedelics for treatment resistant depression: are they game changers?
Kalfas, M., Taylor, R. H., Tsapekos, D., & Young, A. H. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2281582 · Cited by 40
Murray, C. H., Frohlich, J., Haggarty, C. J., Tare, I., Lee, R., & de Wit, H. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-024-01809-2 · Cited by 39
“Low doses provide an attractive therapeutic model if bene fi cial effects of high doses are retained without safety and ethical concerns related to altered states of consciousness [12].”
Copa, D., Erritzøe, D., Giribaldi, B., Nutt, D. J., Carhart-Harris, R. L., & Tagliazucchi, E. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.02.089 · Cited by 39
Breathwork-induced psychedelic experiences modulate neural dynamics
Lewis-Healey, E., Tagliazucchi, E., Canales‐Johnson, A., & Bekinschtein, T. A. (2024) · Cerebral Cortex · doi:10.1093/cercor/bhae347 · Cited by 43
New Frontiers or a Bursting Bubble? Psychedelic Therapy Beyond the Dichotomy
Noorani, T. N., & Martell, J. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.727050 · Cited by 38
Role of Psychedelics in Treatment-Resistant Depression
Kamal, S., Jha, M. K., & Radhakrishnan, R. (2023) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2023.02.004 · Cited by 38
Benefits and Challenges of Ultra-Fast, Short-Acting Psychedelics in the Treatment of Depression
Ramaekers, J. G., Reckweg, J. T., & Mason, N. L. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230890 · Cited by 37
Ethical Issues Regarding Nonsubjective Psychedelics as Standard of Care
Yaden, D. B., Earp, B. D., & Griffiths, R. R. (2022) · Cambridge Quarterly of Healthcare Ethics · doi:10.1017/s096318012200007x · Cited by 41
“5 The rationale for such efforts has been,6 broadly: (1) the subjective effectsmay not have any causal role in the therapeutic effects (as mentioned, this issue has not been scientifically settled), (2) the subjective effects of psychedelics could be harmful to some people (e.”
Informed Consent to Psychedelic-Assisted Psychotherapy: Ethical Considerations
Lee, A., Rosenbaum, D., & Buchman, D. Z. (2024) · The Canadian Journal of Psychiatry · doi:10.1177/07067437231225937 · Cited by 35
“(3) Enhancing Informed Consent Through Trustworthiness: Trust is a foundational value of the therapeutic relationship and is essential to the practice of PAP.”
BackgroundEmmerich, N., & Humphries, B. (2023) · Cambridge Quarterly of Healthcare Ethics · doi:10.1017/s0963180123000099 · Cited by 37
Thal, S. B., Baker, P., Marinis, J., Wieberneit, M., Sharbanee, J. M., Bruno, R., Skeffington, P., & Bright, S. J. (2023) · Clinical Psychology & Psychotherapy · doi:10.1002/cpp.2945 · Cited by 38
A Comprehensive Review of the Current Status of the Cellular Neurobiology of Psychedelics
Banushi, B., & Polito, V. (2023) · Biology · doi:10.3390/biology12111380 · Cited by 37
“This was indicated by a recent study in mice, which showed TrkB binding independent of 5-HT2AR activation [51], and is also consistent with the reports of microdosers who frequently claim clinically relevant benefits without marked subjective effects [209].”
ResultPsychedelics as Novel Therapeutics in Alzheimer’s Disease: Rationale and Potential Mechanisms
Garcia‐Romeu, A., Darcy, S., Jackson, H., White, T., & Rosenberg, P. B. (2021) · Current topics in behavioral neurosciences · doi:10.1007/7854_2021_267 · Cited by 36
Storm on predictive brain: A neurocomputational account of ketamine antidepressant effect
Bottemanne, H., Berkovitch, L., Gauld, C., Balcerac, A., Schmidt, L., Mouchabac, S., & Fossati, P. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105410 · Cited by 33
“As with ketamine, whether the intensity of these subjective effects is positively correlated with antidepressant effects is still debated (Olson, 2021; Yaden and Griffiths, 2021).”
Insights on psychedelics: A systematic review of therapeutic effects
Kugel, J., Laukkonen, R., Yaden, D. B., Yücel, M., & Liknaitzky, P. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106117 · Cited by 32
“…sought to clarify the role of subjective experience in the therapeutic effects of psychedelics, including the administration of psychedelics to people under anaesthesia (Heifets et al., 2024), and the development of psychedelic-like drugs designed to have minimal subjective effects (Olson, 2021).”
Psychedelics, Meaningfulness, and the “Proper Scope” of Medicine: Continuing the Conversation
Cheung, K., Patch, K., Earp, B. D., & Yaden, D. B. (2023) · Cambridge Quarterly of Healthcare Ethics · doi:10.1017/s0963180123000270 · Cited by 31
“3,4,5 Although nonsubjective psychedelics currently do not exist, interest in developing such compounds from private companies and other stakeholders is currently growing.”
A Transformative Trip? Experiences of Psychedelic Use
Neitzke‐Spruill, L., Beit, C. S., Robinson, J. O., Blevins, K. R., Reynolds, J., Evans, N. G., & McGuire, A. L. (2024) · Neuroethics · doi:10.1007/s12152-024-09567-0 · Cited by 31
Kaup, K., Vasser, M., Tulver, K., Munk, M., Pikamäe, J., & Aru, J. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1088896 · Cited by 33
“One possibility is that the underlying mechanisms are strictly neurochemical (30, 31).”
BackgroundPsychedelic experiences and long-term spiritual growth: a systematic review
Schutt, W. A., Exline, J. J., Pait, K. C., & Wilt, J. A. (2024) · Current Psychology · doi:10.1007/s12144-024-06272-2 · Cited by 32
“Although some consider mystical experiences to be crucial to the therapeutic use of psyche-delics (Yaden & Griffiths, 2021), there is some contention around this point (e.g., Olson, 2020).”
Addressing blinding in classic psychedelic studies with innovative active placebos
Aday, J. S., Simonsson, O., Schindler, E. A. D., & D’Souza, D. C. (2025) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaf023 · Cited by 33
“34 If certain aspects of the psychedelic experience, such as mystical-type effects and insight, are crucial therapeutic mechanisms of action with psilocybin, DXM, and other control conditions that closely mimic the subjective effects without providing those elements may make for excellent active…”
Animal Behavior in Psychedelic Research
Odland, A. U., Kristensen, J. L., & Andreasen, J. T. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000590 · Cited by 32
Humphreys, K. N., Korthuis, P. T., Stjepanović, D., & Hall, W. (2024) · Annual Review of Psychology · doi:10.1146/annurev-psych-020124-023532 · Cited by 32
VanderZwaag, J., Halvorson, T., Dolhan, K., Šimončičová, E., Ben‐Azu, B., & Tremblay, M. (2022) · Neurochemical Research · doi:10.1007/s11064-022-03772-0 · Cited by 30
Tabernanthalog Reduces Motivation for Heroin and Alcohol in a Polydrug Use Model
Heinsbroek, J. A., Giannotti, G., Bonilla, J., Olson, D. E., & Peters, J. (2023) · Psychedelic Medicine · doi:10.1089/psymed.2023.0009 · Cited by 32
“48 Although some pharmacological studies have suggested that activation of the 5-HT2A receptor may not be necessary for psychedelic drug-induced neuroplasticity, 14,42 others have used genetic knockout animals to demonstrate a critical role for 5-HT2AR in this process.”
Self-citationPsychedelics as Therapeutics—Potential and Challenges
Volkow, N. D., Gordon, J. A., & Wargo, E. M. (2023) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2023.1968 · Cited by 29
The Mystical Experience Questionnaire 4-Item and Challenging Experience Questionnaire 7-Item
Strickland, J. C., Garcia‐Romeu, A., & Johnson, M. W. (2024) · Psychedelic Medicine · doi:10.1089/psymed.2023.0046 · Cited by 30
“40,41 Brief measures may allow for additional opportunities to test these hypotheses by allowing for more inclusive measurement in clinical protocols and in potential future nonresearch clinical care settings.”
Nautiyal, K. M., & Yaden, D. B. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-022-01424-z · Cited by 28
“There are clear correlations between psychedelic experiences and therapeutic responses [2]; though it is possible that these are not necessary for the clinical effects [3].”
The science of psychedelic medicine
Siegel, J. S., Liston, C. M., Nicol, G. E., Carhart-Harris, R. L., & Bogenschutz, M. P. (2026) · Nature Medicine · doi:10.1038/s41591-025-04194-5 · Cited by 28
“The development of NHPAs stems largely from preclinical work suggesting that psychedelics’ neuroplastic effects can be separated from their hallucinogenic effects 78,195,196 .”
Kaminski, D., & Reinert, J. P. (2023) · Annals of Pharmacotherapy · doi:10.1177/10600280231205645 · Cited by 31
“36 For example, a secondary analysis of a study suggested that based on 5D-ASC data and therapeutic outcomes, finding ways to minimize anxiety and maximize mystical-type experience during the psilocybin experience may influence positive change and may be worth further investigation to maximize…”
The mechanistic divide in psychedelic neuroscience: An unbridgeable gap?
Barksdale, B. R., Doss, M. K., Fonzo, G. A., & Nemeroff, C. B. (2024) · Neurotherapeutics · doi:10.1016/j.neurot.2024.e00322 · Cited by 28
“However, these compounds do produce robust changes in markers of neuroplasticity and demonstrate evidence of possible therapeutic effects in rodent models [41,70,71].”
Background
Metadata
- Authors
- Olson, D. E.
- Affiliations
- University of California, Davis (US)
- Corresponding author
- Olson, David E.
- ORCID
- Olson, David E.
- Venue
- ACS Pharmacology & Translational Science
- Publisher
- American Chemical Society (ACS)
- Published
- 2020-12-10
- Volume
- 4
- Issue
- 2
- Pages
- 563-567
- ISSN
- 2575-9108 (ISSN-L)
- PMC
- PMC8033607
- OpenAlex
- W3112904824
- Cited by
- 329
- References
- 36
- Citations by year
- 2026: 43 · 2025: 70 · 2024: 69 · 2023: 55 · 2022: 58 · 2021: 31 · 2020: 2
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- Locations
- ACS Pharmacology & Translational Science (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institutes of Health (R01GM128997)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cognitive Neuroscience › Pain Management and Placebo Effect
- Keywords
- psychedelics, subjective effects, mystical experience, mood, behavior, neuroplasticity, neuropsychiatric disorders, psychedelic medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.